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between QALY scores and scores on instruments regularly used
in schizophrenia studies such as the PANSS or the CGI, in order
to see if it is possible to construct reliable ‘crosswalks’ between
such clinical measures and the QALY-generating scores.
RESULTS: The limited evidence in the ﬁeld suggests that the cal-
culation of QALYs to quantify the adverse effects of schizo-
phrenia is difﬁcult. Nevertheless, usefulness of such calculation
for a proper estimation of the true burden of schizophrenia
cannot be ignored. Data from a large observational study, fol-
lowing 600 people with schizophrenia over three years, are used
to analyse the correlation between utility-generating scores from
EQ-5D and schizophrenia speciﬁc measures of clinical circum-
stances such as the PANSS, the MADRS, the AIMS measure of
side effects, the Simpson-Angus measure of side effects and the
Barnes Akathisia Rating Scale to see how generic instruments
such as EQ-5D perform in evaluating different health states in
Schizophrenia. CONCLUSIONS: Although the EQ-5D index
does not capture the changes in quality of life associated with
symptoms changes, it may be reasonably valid for calculating
QALYs for patients with schizophrenia.
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OBJECTIVES: 1) To describe the long term evolution of HRQL
of outpatients with schizophrenia, and 2) to analyse its associa-
tion with antipsychotic use. METHODS: SOHO is an ongoing,
3-year, observational study of the treatment of schizophrenia in
ten European countries. The primary objective of SOHO is to
assess the costs and outcomes of treatment of schizophrenia
using antipsychotics. Together with clinical measures, the EQ-
5D (VAS score and tariffs) were administered at baseline, and 3,
6, 12, 18, and 24 months. The ‘panel analysis’ approach was
used, since the outcomes were measured for the distinct post
baseline epochs (0–6, 6–12, 12–18, and 18–24 months of treat-
ment). Multivariate modeling was performed for each epoch,
adjusting for baseline differences among patients. When using
the second and subsequent episodes of patient treatment the
baseline covariates were derived from the covariates collected
when the patient switched treatment. RESULTS: A total of 8109
patients were included in this analysis (44% women; mean age:
40); 24-month retention was 78.47%. Overall, the EQ-5D score
after each period of continuous treatment was: Baseline; mean
0.6 SD 0.32: (0–6 months): 0.76 SD 0.26; (6–12 months): 0.79
SD 0.24 (12–18 months): 0.81 SD 0.23; (18–24 months): 0.82
SD 0.23. Olanzapine-treated patients had statistically higher EQ-
5D utility improvements during the ﬁrst 6 months compared
with risperidone (difference in mean change: 0.041; 95% CI:
0.023–0.06)-, quetiapine (0.032; 0.006–0.059)-, oral (0.081;
0.057–0.105)- and depot typicals (0.077; 0.049–0.105)-treated
patients. No statistical separation was observed between olan-
zapine, clozapine and amilsupride groups. These differences
remain during the 24-month follow-up. CONCLUSIONS:
Antipsychotic treatment is associated with sustained improve-
ment in HRQL. The improvements in EQ-5D scores during the
ﬁrst 6 months for the Olanzapine group were signiﬁcantly higher
than the improvement for other antipsychotics and remaining
thereafter, with the exception of Amilsupride and Clozapine
where no signiﬁcant separation was found.
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OBJECTIVES: To deﬁne criteria for symptoms remission in
depression for reduced versions of the HDRS. METHODS: The
discriminative validity of the HDRS (HDRS-21 and 17 items)
and its shorter scales [Bech Melancholia Scale (BMS-6); Maier
& Philips Severity Scale (MPSS-6); Gibbons et al Depression
Scale (GDS-8); Evans et al Depression Scale (EDS-6)], was
assessed against the Clinical Global Impression of severity (CGI)
in a Spanish multicenter study. The study included 168 depres-
sive patients in ambulatory care. Of these, 118 patients were con-
sidered as clinically unstable (either because of presenting a
new/recurrent disease episode or because of needing an adjust-
ment/change of treatment). After six weeks, those patients were
reassessed by the HDRS and the CGI. The best cut-off points to
discriminate the criterion of clinical remission (CGI score = 1)
were found by using Receiver Operating Characteristic analyses
(ROC). The accuracy of the different versions was assessed by
analysing the area under the ROC curves (AUC). RESULTS: All
versions discriminated at baseline the severity of depression
according to the CGI criterion (all p-values < 0.005 by one-way
ANOVA corrected for multiple comparisons). Also, all versions
discriminated the severity of depression (remission versus no
remission) at six weeks of follow-up (all p-values < 0.0001 by t-
test analyses). The ROC analyses suggested the following cut-off
points to identify remission criteria in our sample (HDRS-21:
<=7; HDRS-17: <=7; BMS: <=2; MPSS: <=3; GDS: <=5; EDS:
<=4). The AUC showed similar accuracy for the HDRS-21,
HDRS-17 and the four shorter versions (AUC range from 0.89
to 0.95, chi2 (ﬁve df) = 8.72, p = 0.12). CONCLUSION: Com-
pared with the canonical versions of the HDRS (21 or 17 items),
shorter versions have showed similar accuracy to deﬁne remis-
sion of depressive symptoms.
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OBJECTIVES: To compare outcomes of patients receiving either
SSRI or SNRI antidepressants for Major Depression in primary-
care settings. METHODS: We analyzed data collected from 
an observational study in 47 primary care facilities in four 
Canadian provinces. Patients meeting DSM-IV-TR criteria for
major depression, >=18 years of age and scoring >=18 on the
HAMD-17 were assigned to groups assessed using HAMD-7 or
HAMD-17. All patients received SSRIs or SNRIs according to
their physician’s preference. Patient outcome was remission
(HAMD-17 <=, or HAMD-7 <=) after 8 treatment weeks.
RESULTS: Of the 337 patients, 159 (47.2%; 66.6% were
females) received SSRIs (citalopram-110, ﬂuoxetine-9, paroxe-
tine-37 and sertraline-3), and 178 (52.8%, 67.4% were females)
received SNRIs (venlafaxine-XR). Mean age was 42.0 ± 13.6 for
SSRIs and 43.7 ± 13.7 for SNRIs (P = 0.60). SSRI-treated
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patients’ scores decreased 67.7% on HAMD-17 and 69.5% on
HAMD-7 (P < 0.05). Improvements in SNRI-treated patients
were similar (64.6% and 63.2%, respectively, P < 0.05). There
were no signiﬁcant differences between groups in response rates
(P = 0.45 for HAMD-17, 0.16 for HAMD-7). Per-protocol (PP)
remission rates measured using HAMD-17 at week 8 were
58.3% for SSRI-treated patients (N = 72) and 48.4% for SNRI-
treated patients (N = 64, P = 0.30). For the HAMD-7 group, PP
remissions were 40.4% for SSRIs (N = 57) and 44.4% for SNRIs
(N = 81, P = 0.73). Intent-to-treat (ITT) remission rates using
HAMD-17 were 46.7% for SSRI-treated patients (N = 90) and
39.2% for SNRI-treated patients (N = 79, P = 0.41). HAMD-7
ITT remission rates were 33.3% for SSRIs (N = 69) and 36.4%
for SNRIs (N = 99; P = 0.81). By 8 weeks, 18.9% dropped out
in the SSRI group and 18.5% in the SNRI group (P = 0.95).
CONCLUSIONS: Large, randomized, controlled, primary care
data are needed to adequately address the question of superior-
ity between SNRIs and SSRIs. Our post –hoc analysis found no
signiﬁcant differences between these two therapeutic groups. Suf-
ﬁciently powered studies comparing the effectiveness of antide-
pressant therapies in real-world settings are urgently needed.
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OBJECTIVES: Compare adults treated with SSRIs and SNRIs
for major depression. METHODS: Identiﬁed all head-to-head
trials comparing SSRIs (citalopram, escitalopram, ﬂuoxetine, ﬂu-
voxamine, paroxetine, sertraline) with SNRIs (venlafaxine-XR,
duloxetine) in therapeutic doses. Outcome: remission 12) at 8
weeks. Two reviewers searched £ 7 or MADRS £ 3 or HAMD-
17 £(HAMD-7 Medline, Embase and Cochrane databases to
identify articles, extract data, adjudicated by a third judge. Rates
were combined using random-effects meta-analytic model. Per-
formed Intent-to-Treat (ITT) and Per-Protocol (PP) 2 assessed
heterogeneity of effects. RESULTS: 25 studies were c analyses.
identiﬁed, 19 were rejected; 6 studies provided 7 head-to-head
trials of 1345 patients (68.0% females per drug). Five RCTs (N
= 1008) and 2 naturalistic trials (N = 337). All displayed non-
heterogeneity (P > 0.05). ITT Remission rates in RCTs: 49.5%
(SE = 6.2%, n = 398) for SNRIs; 39.3% (SE = 10.0%, n = 369)
for SSRIs; meta-analytic difference 9.2% (CI95%:
3.0%–15.4%). PP rates—67.8% (SE = 7.5%, n = 297) for
SNRIs; 56.5% (SE = 10.9%, n = 269) for SSRIs; meta-analytic
difference 9.8% (CI95%:0.2%–19.5%). Naturalistic studies
produced ITT rates of 37.6% (SE = 3.6%, n = 178) for SNRIs;
40.2% (SE = 6.7%, n = 159) for SSRIs; a non-signiﬁcant (P =
0.69) difference of 2.1% favoring SSRIs. PP rates 46.2% (SE =
4.1%, n = 145) for SNRIs; 49.6% (SE = 9.0%, n = 129) for
SSRIs; a difference of 2.9% (P = 0.68) favoring SSRIs. ITT remis-
sion rates were 46.2% (SE = 5.1%, n = 737) for SNRIs; 39.5%
(SE = 7.2%, n = 608) for SSRIs; meta-analytic difference of 6.5%
(CI95%: 0.2%–12.8%). PP rates were 61.8% (SE = 6.9%, n =
571) and 54.5% (SE = 8.1%, n = 450); meta-difference was
6.4% (P = 0.13). CONCLUSIONS: SNRIs seem more efﬁca-
cious. Naturalistic studies produced non-signiﬁcant results dif-
fering from RCT results.
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OBJECTIVES: To compare indirectly the efﬁcacy and safety of
duloxetine and venlafaxine-XR, the two currently available sero-
tonin-norepinephrine reuptake inhibitors (SNRIs) in treating
major depressive disorder. METHODS: Outcomes from pub-
lished, randomized, placebo-controlled trials reporting on mod-
erately-to-severely depressed patients [Hamilton Rating Scale for
Depression (HAM-D) ≥ 15]. A systematic literature search was
performed (1996–January 2005) on Cochrane, EMBASE and
MEDLINE databases. Two independent reviewers judged the
trials for acceptance. Last Observation Carried Forward (LOCF)
data were extracted. Differences in remission (8-week HAM-D
score £7), response (50% decrease on HAM-D), and dropout
rates from lack of efﬁcacy (LOE) and adverse events (AEs) were
meta-analyzed using a random effects model. Each rate was con-
trasted from placebo. RESULTS: Data were acquired from 8
trials from 1754 patients for efﬁcacy and 1791 patients for dis-
continuation/safety. Venlafaxine-XR rates were 17.8% (CI95%:
9.0%–26.5%) and 24.4% (CI95%: 15.0%–37.7%) greater than
placebo for remission and response, compared to 14.2%
(CI95%: 8.9%–26.5%) and 18.6% (CI95%: 13.0%–24.2%) for
duloxetine. Although numerically higher for venlafaxine-XR, no
statistically signiﬁcant differences were found between drugs,
however, both demonstrated overall remission and response rates
signiﬁcantly higher than placebo (p < 0.001). Dropout rates 
due to AEs were, contrasted with placebo, for venlafaxine-XR
6.1% (CI95%: 2.5%–9.7%) and for duloxetine 5.7% (CI95%:
1.5%–10.0%) greater than placebo. Dropout rates due to LOE
were for venlafaxine—XR 10.7% (CI95%: 6.4%–15.1%) and
for duloxetine 11.1% (CI95%: 6.3%–15.9%) less than placebo.
Again, when the two drugs were compared, no statistically sig-
niﬁcant difference was found for both dropout rates. Reported
adverse events were comparable between drugs. CONCLU-
SIONS: Venlafaxine-XR tends to have a favorable trend in remis-
sion and response rates compared to duloxetine, but for dropout
rates and AE these agents did not differ. A direct comparison is
warranted to conﬁrm this tendency.
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OBJECTIVES: To determine the cost effectiveness of a new 
reuptake inhibitor, when compared with -XR in treating major
depressive disorder. METHODS: A cost effectiveness analysis,
using a decision tree modeled outpatient treatment over six
months. Analytic perspectives were those of society (all direct
and indirect costs) and the Ministry of Health of as payer for all
direct costs. Rates of success and dropouts were obtained from
a meta-analysis of placebo-controlled trials. Costs were taken
from standard lists, adjusted to 2005 Canadian dollars; dis-
counting was not applied. One-way sensitivity analyses were 
performed on monthly acquisition costs and success rates;
Monte-Carlo analysis examined all parameters over 10,000 iter-
ations. RESULTS: From both perspectives, outcomes all numer-
ically-XR (Expected success = 53% and 57%, Symptom-free
